Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14855743 | 0.89 | KMT2A (0.38) | TDP1TSHRCYP3A4MEN1KMT2A | |
| SCHEMBL14855765 | 0.89 | TDP1 (0.37) | TDP1TSHRCYP3A4MEN1KMT2A | |
| SCHEMBL10893717 | 0.86 | TDP1 (0.42) | TDP1TSHRCYP3A4MEN1KMT2A | |
| SCHEMBL16511253 | 0.86 | TDP1 (0.37) | TDP1TSHRCYP3A4MEN1KMT2A | |
| SCHEMBL2539675 | 0.81 | POLB (0.31) | CHRNB2CHRNA4 | |
| SCHEMBL21445994 | 0.80 | TDP1 (0.41) | TDP1TSHRCYP3A4MEN1KMT2A | |
| SCHEMBL536216 | 0.78 | — | — | |
| SCHEMBL797852 | 0.76 | — | — | |
| SCHEMBL15567757 | 0.76 | TDP1 (0.47) | TDP1TSHRCYP3A4MEN1KMT2A | |
| SCHEMBL28234478 | 0.75 | TDP1 (0.36) | TDP1TSHRMEN1KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272500-B1 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSITUTED ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2005-05-04 | — | — | EP | claimed |
| US-6437106-B1 | ALKYLATION WITH ALKENYL CARBONATE OR CARBAMATE IN PRESENCE OF PALLADIUM CATALYST AND PHOSPHINE; CYCLIZATION | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | claimed |
| US-11081729-B2 | Non-aqueous electrolyte solution additive, and non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery which include the same | LG CHEM, LTD. | 2021-08-03 | — | — | US | disclosed |
| US-20200044287-A1 | Non-aqueous Electrolyte Solution Additive, and Non-aqueous Electrolyte Solution for Lithium Secondary Battery and Lithium Secondary Battery which Include the Same | LG CHEM, LTD. (KR) | 2020-02-06 | — | — | US | disclosed |
| US-9657030-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657030-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657030-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-05-23 | — | — | US | disclosed |
| US-9624232-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624232-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624232-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-04-18 | — | — | US | disclosed |
| US-9593124-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-03-14 | — | — | US | disclosed |
| EP-1345954-A2 | METHODS UTILIZING ARYL THIOIMINES IN SYNTHESIS OF ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2003-09-24 | — | — | EP | disclosed |
| EP-1272500-A2 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSITUTED ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6455680-B1 | PROTECTING A KETONE OF A KETONE-CONTAINING ERYTHROMYCIN DERIVATIVE AS AN ARYL THIOIMINE (AR-S-N=) BY REACTING THE KETONE WITH A HYDROXYLAMINE TO FORM AN OXIME, AND THEN REACTING WITH A TRIALKYL PHOSPHINE AND AN ARYL DISULFIDE | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
| US-20020115835-A1 | Methods utilizing aryl thioimines in synthesis of erythromycin derivatives | ABBVIE INC. | 2002-08-22 | — | — | US | disclosed |
| US-6437106-B1 | ALKYLATION WITH ALKENYL CARBONATE OR CARBAMATE IN PRESENCE OF PALLADIUM CATALYST AND PHOSPHINE; CYCLIZATION | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| WO-2002050093-A2 | METHODS UTILIZING ARYL THIOIMINES IN SYNTHESIS OF ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2000078773-A2 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSTITUTED ERYTHROMYCIN DERIV ATIVES | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-0196454-B1 | PROCESS FOR REMOVING AN AMINO PROTECTING GROUP | NIPPON ZEON CO., LTD. (JP) | 1990-06-06 | — | — | EP | disclosed |
| EP-0196454-A1 | Process for removing an amino protecting group | NIPPON ZEON CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200044287-A1 | Non-aqueous Electrolyte Solution Additive, and Non-aqueous Electrolyte Solution for Lithium Secondary Battery and Lithium Secondary Battery which Include the Same | LAGE3, KCNN2, CACNA1F | TDP1 2650/4885TSHR 3307/4885CYP3A4 3334/4885 |
| US-20020115835-A1 | Methods utilizing aryl thioimines in synthesis of erythromycin derivatives | CYP2C9, CYP2B6, POR | TDP1 1843/4885TSHR 106/4885CYP3A4 19/4885 |
| US-11081729-B2 | Non-aqueous electrolyte solution additive, and non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery which include the same | LAGE3, KCNN2, CACNA1F | TDP1 2650/4885TSHR 3307/4885CYP3A4 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.